Harte-Hanks Inc Stock News

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harte-Hanks (HHS) could be a great choice. It is one of the several stocks that pass

If you are looking for stocks that are well positioned to maintain their recent uptrend, Harte-Hanks (HHS) could be a great choice. It is one of the several stocks that passed through our "Recent Pric

Harte-Hanks (HHS) delivered earnings and revenue surprises of 680% and 7.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Company to Report Q1 2022 Results on May 12, 2022 CHELMSFORD, Mass. , April 29, 2022 /PRNewswire/ -- Harte Hanks, Inc. (Nasdaq: HHS), a leading global customer experience company, today announced that

The Zacks Advertising and Marketing industry's prospects look good on healthy manufacturing and service activities. OMC, HHS and WPP are likely to be industry frontrunners on digital marketing surge a

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

House Democrats are pressing Health and Human Services Secretary (HHS) Xavier Becerra to protect and expand access to abortion medication and are asking to meet with members of a key HHS task force after the Food an…

Dr. Rachel Levine, the transgender assistant secretary of Health and Human Services (HHS), has been named one of USA Today’s ‘Women of the Year.

President Biden''s Department of Health and Human Services (HHS) is encouraging vaccinated Americans to enroll in "v-safe," a voluntary "after vaccine health checker" to report how they feel post-jab. …

President Biden''s Department of Health and Human Services (HHS) is encouraging vaccinated Americans to enroll in "v-safe," a voluntary "after vaccine health checker" to report how they feel post-jab.

U.S. pharmaceutical company Purdue Pharma, the maker of opioid painkiller OxyContin, has reached a new settlement with eight U.S. states and the District of Columbia to pay up to $6 billion in damages for the company’s role in the U.S. opioid epidemic. The deal, described in a court filing Thursday in White Plains, New York, came after the plaintiffs appealed an earlier settlement late last year, saying it did not properly hold the Sackler family, which owns the drug company, accountable. The new settlement includes more money and other terms, including an apology from the family. In exchange, the settlement provides the Sacklers with protection from further litigation. It does not protect them from criminal prosecution, though there are no charges pending. In a prepared statement, the family said, “While the families have acted lawfully in all respects, they sincerely regret that OxyContin, a prescription medicine that continues to help people suffering from chronic pain, unexpectedly became part of an opioid crisis that has brought grief and loss to far too many families and communities.” The plaintiffs in the case, which include numerous local jurisdictions as well as state attorney generals, maintained Purdue Pharma and members of the Sackler family fueled the U.S. opioid epidemic through deceptive marketing of the highly addictive pain medicine.

On February 23, 2022, the Texas Medical Association was granted summary judgment in its challenge to portions of the second set of implementing regulations that implement the No Surprises Act’s Independent Dispute Resolution (IDR) process. Judge Kernodle of the Eastern District of Texas ruled that HHS and the Departments of Labor and the Treasury (the Departments) violated the Administrative Procedure Act (APA) by substantively rewriting the No Surprises Act in creating a presumptive… By: King & Spalding

In a ruling issued yesterday, a federal judge in Texas ruled that the guidance related to the arbitration process in the No Surprises Act must be vacated. The ruling came down as part of a lawsuit filed by the Texas Medical Association (TMA) against HHS, which is only one of several lawsuits filed challenging the arbitration process created by the Department of Health and Human Services…. By: Nexsen Pruet, PLLC

WASHINGTON, Feb. 25-- America''s Health Insurance Plans issued the following statement:. Matt Eyles, President and CEO of AHIP, issued this statement following a decision rendered in the US District Court for the Eastern District of Texas in Texas Medical Association v. the United States Department of Health and Human Services. Congress passed the No Surprises Act… The post America''s Health Insurance Plans Comments on Court Decision in Texas Medical Association Vs. HHS Surprise Billing Litigation appeared first on InsuranceNewsNet .

SUMMIT, N.J. , Feb. 25, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). 1 The agreement further strengthens the U.S. government''s pandemic preparedness and response capability by ensuring ready production of medical countermeasures (MCMs). This allows BARDA to request that Seqirus provide influenza vaccines and adjuvants for pre-pandemic stockpiling or for manufacture to support rapid response to an influenza pandemic or other public health emergency. Seqirus and BARDA have held similar agreements since 2006. Seqirus stands ready to provide BARDA with: Supply of AUDENZ™ (Influenza A(H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic. 2 The vaccine combines Seqirus'' proprietary MF59 ® adjuvant technology with its cell-based manufacturing platform.